Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

• Irinotecan is employed in the management of colorectal cancer and related disease stages.
• Metastatic colorectal cancer: helps control tumor growth and prolong survival in patients with metastatic disease.
• Advanced colorectal cancer: provides disease stabilization and symptom relief in advanced cases.
• Colorectal cancer (general): used as part of combination chemotherapy regimens to improve treatment outcomes.

• Irinotecan is a prodrug that is converted intracellularly to SN‑38, a potent inhibitor of topoisomerase I. By stabilizing the DNA‑topoisomerase I complex, it prevents relegation of single‑strand breaks, leading to accumulation of DNA damage, inhibition of DNA replication, and ultimately cancer cell death.

Irinotecan therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Diarrhea: often delayed and can be severe.
• Nausea and vomiting: typical chemotherapy‑related symptoms.
• Alopecia: hair loss during treatment cycles.
• Fatigue: generalized tiredness.
• Abdominal cramping: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils requiring urgent care.
• Severe colitis: intense inflammation of the colon.
• Cholinergic syndrome: sweating, lacrimation, and bradycardia.
• Hepatic toxicity: elevated liver enzymes or jaundice.
• Allergic reactions: rash, itching, or anaphylaxis.
• Hemorrhagic cystitis: bladder inflammation with bleeding.

• Prior to initiating Irinotecan therapy, clinicians should assess patient-specific risk factors and monitor for potential complications.
• Monitor blood counts: perform regular complete blood counts to detect neutropenia.
• Assess liver function: evaluate hepatic enzymes before and during treatment.
• Evaluate bowel health: screen for pre‑existing gastrointestinal disorders.
• Use anti‑emetics: prophylactic medication can reduce nausea and vomiting.
• Adjust dose in renal/hepatic impairment: modify regimen based on organ function.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase SN‑38 exposure.
• Enzyme inducers (e.g., rifampin): may reduce therapeutic effect.
• Concurrent myelosuppressive agents: heightened risk of severe neutropenia.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): potential for altered bleeding risk.
• Other antidiarrheal drugs: may mask early signs of severe diarrhea.
• Drugs affecting cholinergic pathways: could exacerbate cholinergic syndrome.